ログイン

Clinical Chem 3"

Clinical Chem 3"
100問 • 1年前
  • John Kenneth Gida
  • 通報

    問題一覧

  • 1

    What process breaks down glycogen during starvation when there is not enough glucose for metabolism?

    Glycogenolysis

  • 2

    Hormone that regulates insulin and glucagon

    Somatostatin

  • 3

    Hormones that are produced in the pancreas in regulation to glucose metabolism

    Insulin, Glucagon, Somatostatin

  • 4

    Cortisol is a hyperglycemic hormone produced in the

    Adrenal cortex

  • 5

    Epinephrine is a hyperglycemic hormone produced in the

    Adrenal medulla

  • 6

    Hyperglycemic hormone that are produced in the Anterior Pituitary

    ACTH, GH

  • 7

    Thyroxine is a hypoglycemic hormone produced in the thyroid; hPL is a hyperglycemic hormone produced in the placenta

    Only the second statement is true

  • 8

    A hypoglycemic disorder that occurs after 10 hours without food; secondary to hyperinsulinism, hormonal deficiencies, genetic disorders, autoimmunity or drug-induced

    Post-absorptive/Fasting

  • 9

    A hypoglycemic disorder that occurs usually within 4 hours after eating a meal

    Post-prandial/Alimentary/Reactive

  • 10

    Symptoms of hypoglycemia begins to appear at

    pgL of 52 mg/dL

  • 11

    Indicated by dizziness, tingling, blurred vision, behavioral changes, seizure, and coma

    Post-absorptive/Fasting

  • 12

    Indicative of tremulousness, palpitations, anxiety, diaphoresis, hunger, and paresthesias

    Post-prandial/Alimentary/Reactive

  • 13

    Panic value for Hypoglycemia

    < or = 40mg/dL

  • 14

    Whipples triad of hypoglycemia

    Symptoms of hypoglycemia, Low plasma glucose level, Relief of symptoms with correction of hypoglycemia

  • 15

    Diagnostic criteria for Insulinoma

    Greater than or equal to 25mg/dL glucose level change

  • 16

    C-peptide is a marker for Type 2 Diabetes

    False

  • 17

    Most abundant ketone form in the body

    B-hydroxybutyrate

  • 18

    Beta cell destruction leading to absolute insulin deficiency

    Type 1 DM

  • 19

    Insulin resistant with progressive insulin deficiency

    Type 2 DM

  • 20

    Type 3a/3.1 DM

    Genetic defects of beta cell function

  • 21

    Type 3b/3.2 DM

    Genetic defects in insulin action

  • 22

    Type 3c/3.3 DM

    Diseases of the exocrine pancreas

  • 23

    Type 3d/3.4 DM

    Endocrinopathies

  • 24

    Type 3e/3.5 DM

    Drug or chemical-induced

  • 25

    Type 3f/3.6 DM

    Infections

  • 26

    Type 3g/3.7 DM

    Uncommon forms of immune-mediated diabetes

  • 27

    Type 3h/3.8 DM

    Other genetic syndromes

  • 28

    This type may convert to type 2 DM in 30-40% of cases within 10 years due to metabolic and hormonal changes

    Type 4

  • 29

    Age of onset is childhood/juvenile; <10% of total frequency

    Type 1

  • 30

    Acute complication/s of Type 1 DM I. DKA II. Neuropathy III. Nephropathy IV. Hyperglycemic hyperosmolar non-ketotic coma HHNC

    I only

  • 31

    Insulin, pro insulin, C-peptide and b-hydroxybutyrate corresponds to diagnosing Insulinoma in which all are increased, except?

    b-hydroxybutyrate

  • 32

    Risk factor for Type 1 DM includes the genetic predisposition of the

    HLA-DR3/DR4

  • 33

    Hypertension is a risk factor for Type 2 DM

    True

  • 34

    This may require insulin injection

    Type 2

  • 35

    Acute complication/s of Type 2 DM I. DKA II. Neuropathy III. Nephropathy IV. Hyperglycemic hyperosmolar non-ketotic coma HHNC

    IV only

  • 36

    Panic value for hyperglycemia

    >/= 500 mg/dL

  • 37

    Symptoms of DM I. Polyuria II. Polydypsia III. Polyphagia IV. Pruritus V. Poor wound healing

    I, II, III, IV, V

  • 38

    Long term microvascular complications of DM I. Nephropathy II. Neuropathy III. Retinopathy IV. CAD V. CVA

    I, II, III

  • 39

    Long term macrovascular complications of DM I. Nephropathy II. Neuropathy III. Retinopathy IV. CAD V. CVA

    IV, V

  • 40

    Adult age of 45 and above is subjected to screening ____ for diagnosis of DM; while individuals with >/= 1 risk factor is _____

    every 3 years; annually

  • 41

    Impaired Fasting plasma glucose level

    100-125 mg/dL

  • 42

    Specimen for HbA1c determination

    EDTA whole blood

  • 43

    6% HbA1c level is considered

    Pre-diabetes

  • 44

    All nondiabetic pregnant women should be screened for GDM at

    late 2nd to early 3rd trimester

  • 45

    In One-Step Method for diagnosing GDM, what is the minimum value of test result/s to meet or exceed in order for a GDM diagnosis?

    One only

  • 46

    In Two-Step Method for diagnosing GDM, what is the minimum value of test result/s to meet or exceed in order for a GDM diagnosis?

    2

  • 47

    glucose is

    10-15% lower in WB

  • 48

    Glycosylated hemoglobin is___

    irreversibly attached to one or both N-terminal valines of the beta-chains

  • 49

    Primarily represents glycosylated albumin

    Fructuosamine

  • 50

    ADA glycemic goal for HbA1c

    <7%

  • 51

    Poor control for HbA1c

    >12%

  • 52

    Fructosamine is unreliable when albumin level is

    </=3 g/dL

  • 53

    Reference range for fructosamine

    205-285 umol/L

  • 54

    Early indicator of diabetic nephropathy

    Microalbuminuria

  • 55

    All are used for monitoring glycemic control except?

    None of the choices

  • 56

    If specimen is delayed for glucose measurement, use NaF/Iodoacetate or SST to prevent glycolysis

    True

  • 57

    Rate of glycolysis if specimen is delayed for glucose determination

    7 mg/dL per h (RT) ; 2 mg/dL per h (4°C)

  • 58

    Effect of dextrose contamination

    10% contamination with 5% dextrose = increase PG of 500 mg/dL

  • 59

    Chemical methods for glucose measurement I. Glucose oxidase II. Ferric reduction III. Hexokinase IV. Copper reduction V. Condensation VI. Glucose dehydrogenase

    II, IV, V

  • 60

    Enzymatic methods for glucose measurement I. Glucose oxidase II. Ferric reduction III. Hexokinase IV. Copper reduction V. Condensation VI. Glucose dehydrogenase

    I, III, VI

  • 61

    Limitations of Copper reduction method I. Specific II. Non-specific III. Subject to false increase result due to presence of other reducing agent

    II, III

  • 62

    Folin - Wu method

    Cu+phosphomolybdic acid - - - >phosphomolybdenum

  • 63

    Nelson-Somogyi method

    Cu+arsenomolybdic acid - - >arsenomolybdenun

  • 64

    Neocuprione method

    Cu+ neocuprione - - - >Cu-neocrupione complex

  • 65

    Phosphomolybdenum is characteristically

    Blue

  • 66

    Arsenomolybdenum is characteristically

    Blue

  • 67

    Neocuprione complex is characteristically

    Yellow-orange

  • 68

    Reducing agent in Ferric Reduction

    Glucose

  • 69

    Ferricyanide is characteristically

    Yellow-orange

  • 70

    Ferrocyanide is characteristically

    Colorless

  • 71

    glucose + o-toluidine ——> schiff's base

    Dubowski mtd

  • 72

    The Dubowski method is more specific than Copper Reduction

    True

  • 73

    Schiff's base

    Green

  • 74

    Converts a-D-glucose to b-D-glucose

    Mutarolase

  • 75

    In the initial reaction of glucose oxidase method for glucose determination, b-D-glucose is oxides to gluconic acid in the presence of?

    Glucose oxidase

  • 76

    Chromogens in the POD-coupled/Trinder reaction I. H2O2 II. 4-aminophenazole III. 4-aminoantipyrine IV. Quinoneimine

    II, III

  • 77

    Color of quinoneimine

    Red/red purple

  • 78

    Polaropgraphic determination for Glucose oxidase method requires addition of _________ to prevent reformation of oxygen

    molybdate and iodide or catalase and ethanol

  • 79

    Reference method for glucose measurement

    Hexokinase

  • 80

    This may be used to enable colorimetric spectrophotometric measurement in the glucose dehydrogenase method of glucose measurement

    Tetrazolium dye

  • 81

    NADH + tetrazolium dye ——> NAD + formazan blue Tetrazolium dye is subsequently converted to formazan blue in the presence of

    Diaphorase

  • 82

    Enzyme/s involved in galactose metabolism I. Galactose-1-phosphate uridyl transfers (GALT) II. Galaktokinase (GALK) III. Uridine diphosphate galactose-4-epimerase (GALE)

    I, II, III

  • 83

    Manifestation of Hepatic glycogenoses

    Hepatomegaly

  • 84

    Enzyme deficient in GSD Type 0

    Glycogen synthase

  • 85

    Enzyme deficient in GSD Type 1a

    Glucose-6-phosphatase

  • 86

    Enzyme deficient in GSD Type 1b

    Glucose-6-phosphatase translocase

  • 87

    Enzyme deficient in GSD Type II

    Lysosomal acid alpha glucosidase

  • 88

    Enzyme deficient in GSD Type IIIa

    Glycogen debranching enzyme

  • 89

    Enzyme deficient in GSD Type IIIb

    Glycogen debranching enzyme

  • 90

    Enzyme deficient in GSD Type IV

    Glycogen branching enzyme

  • 91

    Enzyme deficient in GSD Type V

    Phosphorylase

  • 92

    Enzyme deficient in GSD Type VI

    Glycogen phosphorylase

  • 93

    Enzyme deficient in GSD Type VII

    Phosphofructokinase

  • 94

    Enzyme deficient in GSD Type IX

    Phosphorylase kinase

  • 95

    Enzyme deficient in GSD Type IXb

    Phosphorylase

  • 96

    Enzyme deficient in GSD Type XI

    Glucose transporter 2

  • 97

    Hepatic and Muscle glycogenoses includes

    Cori-Forbes and Type IXb

  • 98

    Muscle glycogenoses includes

    Mc Ardle and Tarui

  • 99

    Hepatic glycogenoses includes

    von Gierke disease, Pompe, Andersen, Her's, Fanconi-Bickel

  • 100

    GSD Type IIIa

    Cori-Forbes

  • Microbiology

    Microbiology

    John Kenneth Gida · 100問 · 1年前

    Microbiology

    Microbiology

    100問 • 1年前
    John Kenneth Gida

    Clinical Chem part 1

    Clinical Chem part 1

    John Kenneth Gida · 100問 · 1年前

    Clinical Chem part 1

    Clinical Chem part 1

    100問 • 1年前
    John Kenneth Gida

    Clinical Chem part 2

    Clinical Chem part 2

    John Kenneth Gida · 100問 · 1年前

    Clinical Chem part 2

    Clinical Chem part 2

    100問 • 1年前
    John Kenneth Gida

    CC part 4

    CC part 4

    John Kenneth Gida · 100問 · 1年前

    CC part 4

    CC part 4

    100問 • 1年前
    John Kenneth Gida

    問題一覧

  • 1

    What process breaks down glycogen during starvation when there is not enough glucose for metabolism?

    Glycogenolysis

  • 2

    Hormone that regulates insulin and glucagon

    Somatostatin

  • 3

    Hormones that are produced in the pancreas in regulation to glucose metabolism

    Insulin, Glucagon, Somatostatin

  • 4

    Cortisol is a hyperglycemic hormone produced in the

    Adrenal cortex

  • 5

    Epinephrine is a hyperglycemic hormone produced in the

    Adrenal medulla

  • 6

    Hyperglycemic hormone that are produced in the Anterior Pituitary

    ACTH, GH

  • 7

    Thyroxine is a hypoglycemic hormone produced in the thyroid; hPL is a hyperglycemic hormone produced in the placenta

    Only the second statement is true

  • 8

    A hypoglycemic disorder that occurs after 10 hours without food; secondary to hyperinsulinism, hormonal deficiencies, genetic disorders, autoimmunity or drug-induced

    Post-absorptive/Fasting

  • 9

    A hypoglycemic disorder that occurs usually within 4 hours after eating a meal

    Post-prandial/Alimentary/Reactive

  • 10

    Symptoms of hypoglycemia begins to appear at

    pgL of 52 mg/dL

  • 11

    Indicated by dizziness, tingling, blurred vision, behavioral changes, seizure, and coma

    Post-absorptive/Fasting

  • 12

    Indicative of tremulousness, palpitations, anxiety, diaphoresis, hunger, and paresthesias

    Post-prandial/Alimentary/Reactive

  • 13

    Panic value for Hypoglycemia

    < or = 40mg/dL

  • 14

    Whipples triad of hypoglycemia

    Symptoms of hypoglycemia, Low plasma glucose level, Relief of symptoms with correction of hypoglycemia

  • 15

    Diagnostic criteria for Insulinoma

    Greater than or equal to 25mg/dL glucose level change

  • 16

    C-peptide is a marker for Type 2 Diabetes

    False

  • 17

    Most abundant ketone form in the body

    B-hydroxybutyrate

  • 18

    Beta cell destruction leading to absolute insulin deficiency

    Type 1 DM

  • 19

    Insulin resistant with progressive insulin deficiency

    Type 2 DM

  • 20

    Type 3a/3.1 DM

    Genetic defects of beta cell function

  • 21

    Type 3b/3.2 DM

    Genetic defects in insulin action

  • 22

    Type 3c/3.3 DM

    Diseases of the exocrine pancreas

  • 23

    Type 3d/3.4 DM

    Endocrinopathies

  • 24

    Type 3e/3.5 DM

    Drug or chemical-induced

  • 25

    Type 3f/3.6 DM

    Infections

  • 26

    Type 3g/3.7 DM

    Uncommon forms of immune-mediated diabetes

  • 27

    Type 3h/3.8 DM

    Other genetic syndromes

  • 28

    This type may convert to type 2 DM in 30-40% of cases within 10 years due to metabolic and hormonal changes

    Type 4

  • 29

    Age of onset is childhood/juvenile; <10% of total frequency

    Type 1

  • 30

    Acute complication/s of Type 1 DM I. DKA II. Neuropathy III. Nephropathy IV. Hyperglycemic hyperosmolar non-ketotic coma HHNC

    I only

  • 31

    Insulin, pro insulin, C-peptide and b-hydroxybutyrate corresponds to diagnosing Insulinoma in which all are increased, except?

    b-hydroxybutyrate

  • 32

    Risk factor for Type 1 DM includes the genetic predisposition of the

    HLA-DR3/DR4

  • 33

    Hypertension is a risk factor for Type 2 DM

    True

  • 34

    This may require insulin injection

    Type 2

  • 35

    Acute complication/s of Type 2 DM I. DKA II. Neuropathy III. Nephropathy IV. Hyperglycemic hyperosmolar non-ketotic coma HHNC

    IV only

  • 36

    Panic value for hyperglycemia

    >/= 500 mg/dL

  • 37

    Symptoms of DM I. Polyuria II. Polydypsia III. Polyphagia IV. Pruritus V. Poor wound healing

    I, II, III, IV, V

  • 38

    Long term microvascular complications of DM I. Nephropathy II. Neuropathy III. Retinopathy IV. CAD V. CVA

    I, II, III

  • 39

    Long term macrovascular complications of DM I. Nephropathy II. Neuropathy III. Retinopathy IV. CAD V. CVA

    IV, V

  • 40

    Adult age of 45 and above is subjected to screening ____ for diagnosis of DM; while individuals with >/= 1 risk factor is _____

    every 3 years; annually

  • 41

    Impaired Fasting plasma glucose level

    100-125 mg/dL

  • 42

    Specimen for HbA1c determination

    EDTA whole blood

  • 43

    6% HbA1c level is considered

    Pre-diabetes

  • 44

    All nondiabetic pregnant women should be screened for GDM at

    late 2nd to early 3rd trimester

  • 45

    In One-Step Method for diagnosing GDM, what is the minimum value of test result/s to meet or exceed in order for a GDM diagnosis?

    One only

  • 46

    In Two-Step Method for diagnosing GDM, what is the minimum value of test result/s to meet or exceed in order for a GDM diagnosis?

    2

  • 47

    glucose is

    10-15% lower in WB

  • 48

    Glycosylated hemoglobin is___

    irreversibly attached to one or both N-terminal valines of the beta-chains

  • 49

    Primarily represents glycosylated albumin

    Fructuosamine

  • 50

    ADA glycemic goal for HbA1c

    <7%

  • 51

    Poor control for HbA1c

    >12%

  • 52

    Fructosamine is unreliable when albumin level is

    </=3 g/dL

  • 53

    Reference range for fructosamine

    205-285 umol/L

  • 54

    Early indicator of diabetic nephropathy

    Microalbuminuria

  • 55

    All are used for monitoring glycemic control except?

    None of the choices

  • 56

    If specimen is delayed for glucose measurement, use NaF/Iodoacetate or SST to prevent glycolysis

    True

  • 57

    Rate of glycolysis if specimen is delayed for glucose determination

    7 mg/dL per h (RT) ; 2 mg/dL per h (4°C)

  • 58

    Effect of dextrose contamination

    10% contamination with 5% dextrose = increase PG of 500 mg/dL

  • 59

    Chemical methods for glucose measurement I. Glucose oxidase II. Ferric reduction III. Hexokinase IV. Copper reduction V. Condensation VI. Glucose dehydrogenase

    II, IV, V

  • 60

    Enzymatic methods for glucose measurement I. Glucose oxidase II. Ferric reduction III. Hexokinase IV. Copper reduction V. Condensation VI. Glucose dehydrogenase

    I, III, VI

  • 61

    Limitations of Copper reduction method I. Specific II. Non-specific III. Subject to false increase result due to presence of other reducing agent

    II, III

  • 62

    Folin - Wu method

    Cu+phosphomolybdic acid - - - >phosphomolybdenum

  • 63

    Nelson-Somogyi method

    Cu+arsenomolybdic acid - - >arsenomolybdenun

  • 64

    Neocuprione method

    Cu+ neocuprione - - - >Cu-neocrupione complex

  • 65

    Phosphomolybdenum is characteristically

    Blue

  • 66

    Arsenomolybdenum is characteristically

    Blue

  • 67

    Neocuprione complex is characteristically

    Yellow-orange

  • 68

    Reducing agent in Ferric Reduction

    Glucose

  • 69

    Ferricyanide is characteristically

    Yellow-orange

  • 70

    Ferrocyanide is characteristically

    Colorless

  • 71

    glucose + o-toluidine ——> schiff's base

    Dubowski mtd

  • 72

    The Dubowski method is more specific than Copper Reduction

    True

  • 73

    Schiff's base

    Green

  • 74

    Converts a-D-glucose to b-D-glucose

    Mutarolase

  • 75

    In the initial reaction of glucose oxidase method for glucose determination, b-D-glucose is oxides to gluconic acid in the presence of?

    Glucose oxidase

  • 76

    Chromogens in the POD-coupled/Trinder reaction I. H2O2 II. 4-aminophenazole III. 4-aminoantipyrine IV. Quinoneimine

    II, III

  • 77

    Color of quinoneimine

    Red/red purple

  • 78

    Polaropgraphic determination for Glucose oxidase method requires addition of _________ to prevent reformation of oxygen

    molybdate and iodide or catalase and ethanol

  • 79

    Reference method for glucose measurement

    Hexokinase

  • 80

    This may be used to enable colorimetric spectrophotometric measurement in the glucose dehydrogenase method of glucose measurement

    Tetrazolium dye

  • 81

    NADH + tetrazolium dye ——> NAD + formazan blue Tetrazolium dye is subsequently converted to formazan blue in the presence of

    Diaphorase

  • 82

    Enzyme/s involved in galactose metabolism I. Galactose-1-phosphate uridyl transfers (GALT) II. Galaktokinase (GALK) III. Uridine diphosphate galactose-4-epimerase (GALE)

    I, II, III

  • 83

    Manifestation of Hepatic glycogenoses

    Hepatomegaly

  • 84

    Enzyme deficient in GSD Type 0

    Glycogen synthase

  • 85

    Enzyme deficient in GSD Type 1a

    Glucose-6-phosphatase

  • 86

    Enzyme deficient in GSD Type 1b

    Glucose-6-phosphatase translocase

  • 87

    Enzyme deficient in GSD Type II

    Lysosomal acid alpha glucosidase

  • 88

    Enzyme deficient in GSD Type IIIa

    Glycogen debranching enzyme

  • 89

    Enzyme deficient in GSD Type IIIb

    Glycogen debranching enzyme

  • 90

    Enzyme deficient in GSD Type IV

    Glycogen branching enzyme

  • 91

    Enzyme deficient in GSD Type V

    Phosphorylase

  • 92

    Enzyme deficient in GSD Type VI

    Glycogen phosphorylase

  • 93

    Enzyme deficient in GSD Type VII

    Phosphofructokinase

  • 94

    Enzyme deficient in GSD Type IX

    Phosphorylase kinase

  • 95

    Enzyme deficient in GSD Type IXb

    Phosphorylase

  • 96

    Enzyme deficient in GSD Type XI

    Glucose transporter 2

  • 97

    Hepatic and Muscle glycogenoses includes

    Cori-Forbes and Type IXb

  • 98

    Muscle glycogenoses includes

    Mc Ardle and Tarui

  • 99

    Hepatic glycogenoses includes

    von Gierke disease, Pompe, Andersen, Her's, Fanconi-Bickel

  • 100

    GSD Type IIIa

    Cori-Forbes